Zandelisib, a PI3Kδ inhibitor on intermittent schedule (IS) in follicular lymphoma patients who progressed within 24 months of first‐line chemoimunotherapy (POD24) Meeting Abstract
| Authors: | Pagel, J.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H.; Kenkre, V. P.; Soumerai, J. D.; Llorin‐Sangalang, J.; Gorbatchevsky, I.; Li, J.; Zelenetz, A. D. |
| Abstract Title: | Zandelisib, a PI3Kδ inhibitor on intermittent schedule (IS) in follicular lymphoma patients who progressed within 24 months of first‐line chemoimunotherapy (POD24) |
| Meeting Title: | 16th International Conference on Malignant Lymphoma - Virtual Edition |
| Journal Title: | Hematological Oncology |
| Volume: | 39 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Jun 18-22 |
| Meeting Location: | Virtual |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-06-01 |
| Start Page: | 173 |
| End Page: | 174 |
| Language: | English |
| ACCESSION: | 150946811 |
| DOI: | 10.1002/hon.25_2880 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 34105791 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 113 -- Accession Number: 150946811 -- Entry Date: In Process -- Revision Date: 20210618 -- Publication Type: Article -- Supplement Title: Jun2021 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: Cinahl |
